Physician profile

James M Morris

Family Medicine · Rusk, TX

NPI 1871520577

$387.84

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$40.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Avanir Pharmaceuticals, INC. $152.72 2019-2022
Neurocrine Biosciences, INC. $68.79 2022-2024 Ingrezza
Sunovion Pharmaceuticals INC. $59.99 2019-2020
Astrazeneca Pharmaceuticals LP $38.35 2019
Urovant Sciences INC $18.51 2022
Abbvie INC. $18.03 2023
Alkermes, INC. $16.44 2020
Teva Pharmaceuticals USA, INC. $15.01 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James M Morris

$387.84

in general payments reported 2019-2025

Years
2019-2024
Top company
Avanir Pharmaceuticals, INC.

https://glasscript.com/doctor/220478/james-m-morris

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.